Alkaline phosphatase =< 2 x ULN (=< 5 x ULN for patients with known liver involvement and =< 7 x ULN for patients with known bone involvement)
Within 3 weeks prior to study registration: \r\nAlkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer) within 3 weeks prior to study registration
Alkaline phosphatase < 2.5 x the ULN or < 5 x the ULN if secondary to liver metastasis
Alkaline phosphatase =< 2.5 x ULN (or =< 5 x ULN for subjects with liver metastasis)
Alkaline (Alk.) phosphatase =< 3 x ULN unless evidence of the direct liver involvement by lymphoma - then =< 5 x ULN obtained =< 14 days prior to registration
Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Alkaline phosphatase =< 2.5 times the ULN (=< 5 x ULN for patients with liver involvement)
Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver or bone involvement of their cancer)
FULL STUDY INCLUSION CRITERIA: Alkaline phosphatase (ALP) limit =< 2.5 x ULN (=< 5 x ULN for patients with liver involvement of their cancer)
Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Alkaline phosphatase =< 3 x ULN (=< 5 x ULN with liver involvement of their cancer)
Alkaline phosphatase =< 3 X ULN unless due to direct lymphoma involvement, and then =< 5 X ULN
Alkaline phosphastase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Alkaline phosphatase =< 2 x ULN (=< 5 x ULN for patients with known liver involvement and =< 7 x ULN for patients with known bone involvement)
Alkaline phosphatase limit =< 2.5 x ULN (=< 5.0 x ULN for subjects with intrahepatic involvement of their cancer)
Alkaline phosphatase =< 2 x ULN (=< 5 x ULN for patients with known liver involvement and =< 7 x ULN for patients with known bone involvement)
Alkaline phosphatase levels ? 2.5 × ULN (? 5 × ULN in subjects with liver metastasis)
Alkaline (Alk.) phosphatase =< 3 x ULN unless evidence of the direct liver involvement by lymphoma – then =< 5 x ULN
alanine transaminase, aspartate aminotransferase and alkaline phosphatase ?3 × ULN or <5 × ULN in cases of liver involvement
Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Alkaline phosphatase =< 3 x ULN (=< 5 x ULN if liver or bone involvement)
Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for patients with liver involvement of their cancer) (obtained =< 7 days prior to randomization)
Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Alkaline phosphatase =< 2.5 x ULN; unless elevated secondary to lymphoma involvement of the liver
Alkaline phosphatase =< 3 x ULN (=< 5 x ULN with liver involvement of their cancer)
Alkaline phosphatase limit <2.5 x ULN (<5 x ULN for subjects with liver involvement of their cancer)
Alkaline phosphatase levels ? 2.5 × ULN (? 5 × ULN in subjects with liver metastasis)
Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver or bone involvement of their cancer)
Alkaline Phosphatase =< 2 x ULN (=< 5 x ULN for patients with known liver involvement and =< 7 x ULN for patients with known bone involvement)
Alkaline phosphatase limit ? 2.5 x ULN (? 5 x ULN for subjects whose cancer involves their liver).
Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Alkaline phosphatase =< 3 x ULN, unless evidence of direct liver involvement by lymphoma, then =< 5 x ULN
Alkaline phosphatase =< 3 x ULN unless due to direct lymphoma involvement, and then =< 5 x ULN
Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Alkaline phosphatase =< 1.5 x the institutional ULN
Alkaline phosphatase (ALK Phos) =< 2.5 x institutional ULN
Alkaline phosphatase =< 1.5 x IULN within 28 days prior to registration
Within 6 weeks prior to randomization: Alkaline phosphatase must be =< 2.5 x ULN for the lab
Alkaline phosphatase =< 2.5 x ULN (CTCAE v 3.0 grade 0-1)
Alkaline phosphatase =< 3 x ULN
Alkaline phosphatase =< 1.5 x institutional ULN, within 21 days prior to registration
Alkaline phosphatase =< 2 x IULN
Patients must have alkaline phosphatase =< 2.5 x IULN within 14 days prior to registration
Alkaline phosphatase less than or equal to 2.5 x ULN (CTCAE grade 1)
Alkaline phosphatase =< 3X the institutional ULN
Alkaline phosphatase ? 2.5 x ULN, unless the elevated alkaline phosphatase is due to bone metastasis.
Alkaline phosphatase ? 2.5 × ULN;
Alkaline phosphatase =< 2 × ULN (=< 5 × ULN if considered due to tumor)
Alkaline phosphatase < 5 times ULN
AST and/or ALT > 1.5 x ULN with concomitant alkaline phosphatase > 2.5 x ULN
Serum alkaline phosphatase =< 5 x institutional ULN
Alkaline phosphatase =< 3 × ULN
Alkaline phosphatase > 3 ULN
Alkaline phosphatase should be less than or equal to 2.5 x ULN (CTCAE v4.0, grade 1)
Have an alanine aminotransferase (ALT) ?3.0 × ULN. (Note: There are no specific requirements for AST or alkaline phosphatase.)
alkaline phosphatase must be ? 2.5 x ULN for the lab; and
Alkaline phosphatase =< 2.5 x ULN; (=< 5 x ULN in case of bone metastasis)
Alkaline phosphatase =< 2.5 x ULN, within 14 days prior to registration
Alkaline phosphatase =< 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x upper limit of normal (ULN) with alkaline phosphatase =< 2.5 x ULN OR AST and ALT =< 1.5 x ULN, with alkaline phosphatase > 2.5 x ULN
ARM 2 - A: AST/ALT/alkaline phosphatase: =< 5 x ULN
Alkaline phosphatase =< 3 x ULN =< 28 days prior to registration
Alkaline phosphatase up to 2.5 x ULN.
COHORT B ONLY: Obtained =< 14 days prior to registration: alkaline phosphatase =< 750 U/L
Alkaline phosphatase =< 2.5 x ULN
Alkaline phosphatase less than 1.5 times ULN (grade 1)
Alkaline phosphatase =< 2.5 x ULN
ALT or aspartate AST > 1.5 x ULN concomitant with alkaline phosphatase > 2.5 x ULN
AST and ALT =< 1.5 x ULN, with alkaline phosphatase > 2.5 x ULN
Alkaline phosphatase < 2.5 × ULN
Serum alkaline phosphatase =< 5 X ULN
Obtained =< 14 days prior to registration: Alkaline phosphatase =< 3 x ULN
Alkaline phosphatase =< 2.5 x ULN for the institution within 14 days of study registration
Alkaline phosphatase less than or equal to 2.5 x ULN (CTCAE v4.03 grade 1)
Alkaline phosphatase =< 5 x ULN must be met during screening (within 21 days) and also prior to study drug administration on cycle 1 day 1
Within 14 days prior to registration: Alkaline phosphatase =< 2.5 x ULN
Alkaline phosphatase < 4 x ULN.
Alkaline phosphatase (alk phos) < 2.5 X ULN
Alkaline phosphatase =< 2.5 X ULN
Alkaline (Alk) phosphatase < 2.5 x ULN
Hepatic impairment, defined as alkaline phosphatase =< 2 x institutional ULN, within 21 days of initiation of protocol therapy
Hepatic impairment, defined as alkaline phosphatase > 2 x institutional ULN, within 21 days of initiation of protocol therapy
Alkaline phosphatase =< 3 x ULN
Determined within 3 weeks of treatment initiation: Alkaline phosphatase < 5 x ULN
Alkaline phosphatase =< 2.5 x ULN prior to biopsy
Obtained =< 7 days prior to registration: Alkaline phosphatase < 5 x ULN
Alkaline phosphatase =< 2.5 x ULN
Alkaline phosphatase < 3 x ULN
Alkaline phosphatase > 2.5 x ULN
Alkaline phosphatase =< to 2.5 x ULN
Alkaline phosphatase < 5 x ULN obtained =< 7 days prior to registration
Alkaline phosphatase =< 2.5 x institutional ULN obtained within 14 days of first treatment
Alkaline phosphatase =< 2.5 x ULN, unless elevation is thought to be due to hepatic infiltration by the hematologic malignancy
Alkaline phosphatase =< 2.5 x ULN
Alkaline phosphatase (Alk phos) =< 5 X ULN
Alkaline Phosphatase less than 2.5 x ULN (CTCAE Grade 1)
Alkaline phosphatase (liver fraction) =< 2.5 X ULN; if AST or ALT is > 2.5 X ULN, then liver fraction of alkaline phosphatase should be =< 2.5 X ULN
Alkaline phosphatase > 2.5 x ULN
Alkaline phosphatase (AP) ? 2.5 x ULN, unless considered due to organ leukemic involvement;
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x upper limit of normal (ULN) with alkaline phosphatase =< 2.5 x ULN OR AST and ALT =< 1.5 x ULN, with alkaline phosphatase > 2.5 x ULN
Alkaline phosphatase (alk phos) < 2.6 x ULN
Alkaline phosphatase =< 1.5 x ULN, obtained =< 14 days prior to registration
Alkaline phosphatase =< 2.5 x ULN
Alkaline phosphatase =< 2.5 x ULN
Alkaline phosphatase < 5 x ULN
Alkaline phosphatase =< 2.5 x ULN
Alkaline phosphatase =< 2.5 ULN
Alkaline phosphatase > 2.5 x ULN
Alkaline phosphatase < 5 x ULN
Alkaline phosphatase < 2.5 x ULN
Serum alkaline phosphatase =< 5 x ULN
Alkaline phosphatase < 5 x ULN
Alkaline phosphatase =< 2 x ULN or considered not clinically significant
Obtained =< 14 days prior to registration: Alkaline phosphatase =< 750 U/L
Alkaline phosphatase ?2.0×ULN.
Alkaline phosphatase ?5 x ULN
ORAL CAVITY SQUAMOUS CELL CARCINOMA COHORT: Alkaline phosphatase < 2 x ULN
Alkaline phosphatase < 2.5 X ULN
Alkaline phosphatase < 252 u/L
Alkaline phosphatase < 2.0 x ULN
Alkaline phosphatase must be =< 3 x ULN for the lab within 28 days before randomization
Alkaline phosphatase =< 2.5 x ULN
Alkaline phosphatase (ALK Phos) < 2.5 x ULN
Alkaline phosphatase =< 2.5 x ULN; if liver involvement, alkaline phosphatase =< 5.0 x ULN
Alkaline phosphatase =< 2.5 x ULN for the institution
Alkaline phosphatase must be =< 2.5 x ULN for the lab
Alkaline phosphatase and AST may not both be > the ULN; for example, if the alkaline phosphatase is > the ULN but =< 2.5 x ULN, the AST must be =< the ULN; if the AST is > the ULN but =< 1.5 x ULN, the alkaline phosphatase must be =< ULN; Note: If alanine aminotransferase (ALT) is performed instead of AST (per institution's standard practice), the ALT value must be =< 1.5 x ULN; if both were performed, the AST must be =< 1.5 x ULN
Alkaline phosphatase =< 2.5 x ULN
Alkaline phosphatase =< 2.5 x ULN
Alkaline phosphatase less than or equal to 2.5 x ULN (CTEP CTCAE version 4.0, grade 1)
Alkaline phosphatase =< 2.5 x ULN
Alkaline phosphatase >= 2 x institutional ULN, within 21 days of initiation of protocol therapy
Alkaline phosphatase =< 2.5 x upper limit of normal (ULN); patients with hepatic and/or bone metastases: alkaline phosphatase =< 5 x ULN
Alkaline phosphatase >= 2 x ULN
Alkaline phosphatase =< 2 x IULN be obtained within 42 days prior to registration
Alkaline phosphatase =< 1.5 x ULN (institutional)
Alkaline phosphatase ? 5 x ULN
Alkaline phosphatase =< 2.5 x ULN for the institution
Alkaline phosphatase less than or equal to 2.5 x ULN
Alkaline phosphatase greater than 2.5 x ULN (CTCAE v4.0 grade 1) (if known hepatic metastases alkaline phosphatase may be =< 5 x ULN)
Alkaline phosphatase* less than or equal to 2.5 x ULN
Alkaline phosphatase =< 1.5 UNL
alkaline phosphatase must be less than or equal to 2 x ULN; and
Alkaline phosphatase < 5 x ULN
Alkaline phosphatase =< 2.5 x ULN
Alkaline phosphatase ?2.0×ULN
Alkaline phosphatase limit ? 2.5 x ULN
Alkaline phosphatase less than or equal to 3 x ULN
Alkaline phosphatase less than or equal to 2.5 x ULN
Alkaline phosphatase < or equal to 4 x ULN if not related to leukemic disease
Alkaline phosphatase ? 2.5 x ULN
Alkaline phosphatase within 5 times ULN
Alkaline phosphatase ? 5X ULN
Alkaline phosphatase =< 2.5 x ULN
Alkaline (Alk.) phosphatase =< 3 x ULN
Alkaline phosphatase: ? 2.5 x ULN
Alkaline phosphatase =< 2.5 x ULN obtained =< 14 days prior to registration
Alkaline phosphatase > 3 x institutional ULN, within 21 days of initiation of protocol therapy
Alkaline phosphatase =< 3 x ULN
Alkaline phosphatase (AP) =< 2.0 x ULN
Alkaline phosphatase < 2 X institutional ULN
Alkaline phosphatase < 2.5 x ULN
Alkaline phosphatase =< 2.5 x ULN
Alkaline phosphatase =< 5 x ULN
Alkaline phosphatase =< 5.0 x ULN
Alkaline phosphatase =< 1.5 x IULN
Alkaline phosphatase < 5 x ULN
Alkaline phosphatase >= 2.5 times ULN
Alkaline phosphatase > 3 x ULN
Alkaline phosphatase > 2 x institutional ULN
Alkaline phosphatase =< 2.5 x ULN
Serum alkaline phosphatase should be =< 1.5 x institutional ULN
Alkaline phosphatase (Alk Phos) =< 2.5 x ULN
Alkaline (Alk) phosphatase < 2.5 x ULN
Obtained =< 7 days prior to registration: Alkaline phosphatase =< 3 x ULN
Alkaline phosphatase >= 3 x ULN
Alkaline phosphatase ? 2.5 x ULN
Alkaline phosphatase =< 2.5 x ULN
Alkaline phosphatase =< 2.5 x ULN
Alkaline phosphatase =< 2.5 X ULN
Alkaline phosphatase =< 2.5 x ULN for the institution
Alkaline phosphatase =< 2.5 x ULN, CTCAE grade 1
Alkaline phosphatase < 2.5 x ULN
Alkaline phosphatase no greater than 1.5 times ULN
Alkaline phosphatase =< 2.5 x ULN
Alkaline phosphatase less than or equal to 2.5 x ULN
Alkaline phosphatase values within the institutional ULN
Alkaline phosphatase =< 2.5 X ULN
Alkaline phosphatase =< 2.5 x ULN
Alkaline phosphatase =< 2.5 x ULN
Alkaline phosphatase =< 2.5 x ULN
Alkaline phosphatase < 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) and alkaline phosphatase must be within the eligible; in determining eligibility, the more abnormal of the two values (AST or ALT) should be used; patients with alkaline phosphatase elevation secondary to the bony metastases rather than liver dysfunction may proceed with treatment on protocol after discussion with the principal investigator
Alkaline phosphatase > 1 x ULN but =< 2.5 x ULN and AST or ALT =< ULN eligible
Alkaline phosphatase > 2.5 x ULN but =< 5 x ULN and AST or ALT =< ULN eligible
Alkaline phosphatase > 5 x ULN and AST or ALT =< ULN ineligible
Alkaline phosphatase =< ULN and AST or ALT > 1 x ULN but =< 1.5 x ULN eligible
Alkaline phosphatase > 1 x ULN but =< 2.5 x ULN and AST or ALT > 1 x ULN but =< 1.5 x ULN eligible
Alkaline phosphatase > 2.5 x ULN but =< 5 x ULN and AST or ALT > 1 x ULN but =< 1.5 x ULN ineligible
Alkaline phosphatase > 5 x ULN and AST or ALT > 1 x ULN but =< 1.5 x ULN ineligible
Alkaline phosphatase =< ULN and AST or ALT > 1.5 x ULN but =< 5 x ULN eligible
Alkaline phosphatase > 1 x ULN but =< 2.5 x ULN and AST or ALT > 1.5 x ULN but =< 5 x ULN ineligible
Alkaline phosphatase > 2.5 x ULN but =< 5 x ULN and AST or ALT > 1.5 x ULN but =< 5 x ULN ineligible
Alkaline phosphatase > 5 x ULN and AST or ALT > 1.5 x ULN but =< 5 x ULN ineligible
Alkaline phosphatase =< ULN and AST or ALT > 5 x ULN ineligible
Alkaline phosphatase > 1 x ULN but =< 2.5 x ULN and AST or ALT > 5 x ULN ineligible
Alkaline phosphatase > 2.5 x ULN but =< 5 x ULN and AST or ALT > 5 x ULN ineligible
Alkaline phosphatase > 5 x ULN and AST or ALT > 5 x ULN ineligible
Alkaline phosphatase less than or equal to 2.5 x ULN (CTCAE v4.0 grade 1)
Alkaline phosphatase < 3 x ULN
Alkaline phosphatase =< 2 X ULN
Alkaline phosphatase =< 2.5 times ULN
Alkaline phosphatase ? 2.5 times the ULN
Alkaline phosphatase =< 2.5 x ULN for the institution
Alkaline phosphatase =< 2.5 x ULN
Alkaline phosphatase =< 2.5 x IUNL
Alkaline phosphatase (AP) must be within the range allowing for eligibility, as follows:\r\n* =< ULN\r\n* =< 2.5 x ULN\r\n* =< 5 x ULN
Alkaline phosphatase =< 2.5 x ULN
Alkaline phosphatase =< 3.0 x ULN; if liver involvement, alkaline phosphatase =< 5.0 x ULN
Alkaline phosphatase must be =< 2.5 x ULN for the lab
Alkaline phosphatase and AST/ALT may not both be > the ULN; for example, if the alkaline phosphatase is > the ULN but =< 2.5 x ULN, then the AST/ALT must be =< the ULN; if the AST/ALT is > the ULN but =< 1.5 x ULN, then the alkaline phosphatase must be =< ULN
Patients with AST/ALT or alkaline phosphatase > ULN must have liver imaging that does not demonstrate metastatic disease
Alkaline phosphatase above 2.5X the ULN
Alkaline phosphatase =< 5 x UNL
Alkaline phosphatase of =< 2 ULN
The subject has aspartate aminotransferase and/or alanine aminotransferase > 1.5 × ULN, with concomitant alkaline phosphatase > 2.5 × ULN.
Alkaline phosphatase limit =< 2.5 x ULN
Alkaline phosphatase (Alk phos) =< 3.0 x ULN
Alkaline phosphatase =< to 2.5 x ULN
Alkaline phosphatase =< 5 x institutional ULN obtained =< 7 days prior to registration
Part 2 only: plasma total bilirubin <= ULN; ALT and/or AST <= 1.5 X ULN concomitant with alkaline phosphatase <= 2.5 X ULN.
Part 2 only: Patients with plasma total bilirubin > ULN; ALT and/or AST > 1.5 X ULN concomitant with alkaline phosphatase > 2.5 X ULN.
Alkaline phosphatase =< 2.5 × ULN (patients with hepatic and/or bone metastases: alkaline phosphatase =< 5 × ULN)
Liver: hepatomegaly on physical exam with elevated alkaline phosphatase > 1.5 x ULN
Alkaline phosphatase ? 5 x ULN
Alkaline phosphatase < 2.5 x ULN
Alkaline phosphatase =< 2.5 x ULN
Alkaline phosphatase =< 2.5 x ULN; except for patients with hepatic and/or bone metastases: alkaline phosphatase =< 5 x ULN
Alkaline phosphatase < 2 x ULN (< 5 x ULN in subjects whom the PI and sponsor agree that clinical data suggest extrahepatic source of elevation)
Alkaline phosphatase (AP) =/< 2.5 x ULN
Alkaline phosphatase less than or equal to 2.5 x ULN (CTCAE grade 1)
Alkaline phosphatase =< 1.5 x ULN
Alkaline phosphate =< 2.5 x ULN (within four weeks prior to the study)
Alkaline phosphatase < 2 times ULN, unless arising from bone
Alkaline phosphatase =< 5 x ULN
Alkaline phosphatase =< 2.5 x ULN
Alkaline phosphatase limit =< 2.5 x ULN
Alkaline phosphatase < 2 times ULN, unless arising from bone
Alkaline phosphatase less than or equal to 2.5 x ULN
Alkaline phosphatase limit =< 2.5 x ULN
Serum alkaline phosphatase < 2 x ULN, or considered not clinically significant by the study doctor or designee
Alkaline phosphate > 1.5 x ULN
Patients with plasma alkaline phosphatase greater than 190 IU/dL
Alkaline phosphatase =< 2.5 x ULN
Serum alkaline phosphatase level >= 300 IU/L.
Alkaline phosphatase ? 2.5 x ULN
Alkaline phosphatase < 5 x ULN
Alkaline phosphatase < 4 x ULN
Alkaline phosphatase =< 1.5 x ULN
Alkaline phosphatase < 2 x ULN
Alkaline phosphatase < 2 x ULN
Alkaline phosphatase =< 1.5 x institutional ULN
Alkaline phosphatase > 2.5 x ULN
Alkaline phosphatase < 2.5 x ULN
Alkaline phosphatase =< 2.5 time ULN
Alkaline phosphatase =< 2 X ULN
Alkaline phosphatase =< 2.5 x IULN
Alkaline phosphatase (ALK phos) within 2 x ULN
Alkaline phosphatase =< 2.5 x IULN
Alkaline phosphatase (AP) =< 3 X ULN, obtained within 14 days prior to PET scan
Alkaline phosphatase < 3 x ULN
Alkaline phosphatase =< 5 x ULN
Alkaline phosphatase < 2.5 x ULN
Alkaline phosphatase =< 190 IU/dL
Patients with plasma alkaline phosphatase greater than 190 IU/dL
Alkaline phosphatase ? 2.5 x ULN
Gamma-glutamyl transferase (GGT) alkaline phosphatase ? 2.5 × ULN.
Gamma-glutamyl transpeptidase (GGT): 0-45 U/L
Gamma-glutamyltransferase =< 2.5 x ULN
Gamma-glutamyl transpeptidase (GGT) must be =< 2.5 x institutional upper limit of normal (grade 1 or less per CTCAE 4)
For LY3300054 + abemaciclib only: No participants with liver metastases. Participants must have normal aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, direct bilirubin, gamma-glutamyl transferase (GGT) and alkaline phosphatase (AP).
Alkaline phosphatase (ALP) =< 3 x ULN; if ALP is > 3 x ULN, gamma glutamyl transpeptidase (GGT) must be checked and be =< 3 x ULN (must be within 7 days of MLA)
Aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (GGT), creatine phosphokinase (CPK), lactate dehydrogenase (LDH), alkaline phosphatase (Alk phos) =< 2.5 X the ULN
Gamma-glutamyl transpeptidase (GGT), lactate dehydrogenase (LDH), and alkaline phosphatase =< 2.5 x institutional ULN
Gamma-glutamyl transpeptidase (GGT) > 2.5 x ULN if alkaline phosphatase > 2.5 x ULN obtained < 2 weeks prior to study enrollment
Gamma-glutamyl transferase (GGT) > 2.5 x ULN IF alkaline phosphatase > 2.5 x ULN
Gamma glutamyl transpeptidase (GGT) > 2.5 x ULN IF alkaline phosphatase > 2.5 x ULN
Gamma-glutamyl transpeptidase (GGT) less than 4.0 times below or above the upper or lower limit range
Gamma-Glutamyl Transpeptidase (GGT) > 2.5 x ULN IF alkaline phosphatase > 2.5 x ULN
Gamma-glutamyltransferase (GGT) > 2.5 x ULN
Gamma glutamyl transferase (GGT) > 2.5 x ULN IF alkaline phosphatase > 2.5 x ULN
Alkaline phosphatase equal or less than 1.5 times the upper limit of normal (ULN)
AST (SGOT), ALT (SGPT) and Alkaline phosphatase 2.5 times upper limit of normal (if liver metastases are present, then 5 x ULN is allowed)
Within 30 days prior to enrollment: Alkaline phosphatase equal or less than 1.5 times the upper limit of normal (ULN)
Alkaline phosphatase =< 4 times the upper limit of normal (unless clinically considered to be related to liver involvement with leukemia)
Alkaline phosphatase =< 2.5 times the upper limit of normal
Alkaline phosphatase (Alk Phos) greater than 2.5 times the upper limit of normal
Alkaline phosphatase =< 2 times upper limit normal
Serum alkaline phosphatase less than 2.5 times the upper limits of normal
Alkaline phosphatase =< 3 times the upper limit of normal
Alkaline phosphatase < 2.5 times the upper limit of normal
Alkaline phosphatase < 5 times the upper limit of normal
Alkaline phosphatase < 2.5 times normal
Serum alkaline phosphatase less than 2.5 times the upper limits of normal within 7 days prior to starting treatment in the absence of liver metastasis; in the presence of liver metastasis serum alkaline phosphatase less than or equal to 5.0 times the upper limits of normal within 7 days prior to starting treatment
Alkaline phosphatase < 4 times the upper limit of institutional normal
Alkaline phosphatase must be no more than 2.5 times upper limit of normal unless due to disease involvement of the liver
Alkaline phosphatase < 5 times upper limit of normal
Performed within 14 days prior to study: Alkaline phosphatase < 3 times the upper limits of the institutional normal
Alkaline phosphatase < 3 times upper limit of institutional normal
Serum alkaline phosphatase < 3 times the upper limit of normal (ULN), unless due to liver or bone involvement by HL; under these circumstances, serum alkaline phosphatase must be < 5 x ULN
Alkaline phosphatase within 3 times the upper limits of normal
Alkaline phosphatase =< 3 times the institutional upper limit of normal
Alkaline phosphatase < 2.5 times institutional upper normal limit (unless due to disease involvement of the liver or bone marrow)
Alkaline phosphatase < 3 times normal
Patient has poor liver function (> 2.5 times normal of alkaline phosphatase [Alk phos]) suggestive of cirrhosis or steatohepatitis
Alkaline phosphatase =< 2.5 times upper limit of normal (unless due to disease involvement of the liver or bone marrow)
Alkaline phosphatase > 2.5 times upper normal limit (unless due to chronic GVHD)
Alkaline phosphatase =< 2.5 times upper limit of normal
Alkaline phosphatase less than 10 times the upper limit of normal (unless due to active myositis)
Alkaline phosphatase < 3 times the upper limit of laboratory normal
Alkaline phosphatase =< 3 times upper limit of laboratory normal
Alkaline phosphatase =< 5.0 times the upper limit of normal unless hepatic dysfunction is related to liver involvement with disease
Alkaline phosphatase < 2.5 times the upper limit of normal; in patients with liver metastasis, liver function tests should be < 5 times the upper limit of normal
Alkaline phosphatase (hepatic) > 3 times the upper normal limit
Serum alkaline phosphatase less than 2.5 times the upper limits of normal
Alkaline phosphatase (hepatic) > 3 times the upper normal limit
Alk phosphatase =< 3 times institutional upper limit of normal
Alkaline phosphatase < 3 times the upper limit of normal (alkaline phosphatase and aspartate aminotransferase [AST] cannot both exceed the upper limit of normal)
AST < 3 times upper limit of normal (alkaline phosphatase and AST cannot both exceed the upper limit of normal)
Alkaline phosphatase (ALP) must be < 2 times the upper limit of normal
Alkaline phosphatase (ALK phos) less than 4.0 times below or above the upper or lower limit range
Alkaline phosphatase (ALK phos) less than 4.0 times below or above the upper or lower limit range
Alkaline phosphatase =< 2 times the upper limit of normal
Alkaline phosphatase (ALP) =< 2.5 x ULN measured within 28 days prior to randomization
Adequate liver function as evidenced by bilirubin less than or equal to 1.5 times the ULN and alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than or equal to 3 X ULN (in the case of liver metastases less than or equal to 5 X ULN). In case ALP is greater than 3 X ULN (in the absence of liver metastases) or greater than 5 X ULN (in the presence of liver metastases) AND the participant also is known to have bone metastases, the liver specific ALP must be separated from the total and used to assess the liver function instead of the total ALP
Alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ?3× the ULN (in the case of liver metastases ?5× the ULN). Participants with bone metastases with ALP values greater than 3 times can be included.
Alkaline phosphatase (ALP) =< 3.0 x ULN
Alkaline phosphatase (ALP) =< 5.0 x ULN, at the screening visit
Alkaline phosphatase (ALP) ? 2.5 × ULN (? 5 × ULN if disease-related/in the case of liver metastases).
Patients with isolated elevations in alkaline phosphatase (ALP) < 5 x ULN in the presence of bony disease are not excluded from participating in the study
Serum alkaline phosphatase (ALP) > 2 x ULN
Alkaline phosphatase (ALP) =< 2.5 x ULN or =< 5.0 x ULN for patients with bone metastases
Serum alkaline phosphatase (ALP) =< UNL or =< 2.5 x upper limit of normal (ULN) in case of liver and bone metastases
Alkaline phosphatase (ALP) > or = 5 x upper limit of normal (ULN).
Alkaline phosphatase (ALP) =< 5.0 x ULN
Within 14 days prior to the first study treatment (cycle 1, day 1): Alkaline phosphatase (ALP) =< 2.0 x ULN with the following exception:\r\n* Patients with documented liver involvement or bone metastases: ALP =< 5 x ULN
Total bilirubin and alkaline phosphatase (ALP) =< 2 x ULN or =< 3 x ULN for Gilbert's disease
Alkaline phosphatase (ALP) < 2.5 x ULN
Alkaline phosphatase (ALP) =< 2.5 x ULN for the laboratory\r\n* Note: If ALP is > 1.5 x ULN, imaging to rule out bone and liver metastasis is required
Alkaline phosphatase =< 2.5 x ULN with the following exception; alkaline phosphatase (ALP) =< 5 x ULN in patients with bone metastases
Alkaline phosphatase (ALP) =< 2.5 x ULN
Alkaline phosphatase (ALP) < 2.5 x ULN (3 x ULN for subjects on chronic anticonvulsive therapies).
Alkaline phosphatase (ALP) =< 5.0 x ULN
Alkaline phosphatase (Alp) =< 2.5 x upper limit of normal (ULN)
Alkaline phosphatase (ALP) =< 2 x ULN
CAPMATINIB INCLUSION CRITERIA: Alkaline phosphatase (ALP) =< 5 x ULN
CERITINIB INCLUSION CRITERIA: Alkaline phosphatase (ALP) =< 5 x ULN
PHASE I: Alkaline phosphatase (ALP) < 2.5 x ULN
Alanine aminotransaminase (ALT), Aspartate aminotransaminase (AST) or alkaline phosphatase (ALP) > 2.5 ULN without hepatic metastases or ALT, AST or ALP > 5 ULN with hepatic metastases
Alkaline phosphatase (ALP) =< 5.0 x ULN
Alkaline phosphatase (ALP) =< 3 x ULN; if ALP is > 3 x ULN, gamma glutamyltransferase (GGT) must be checked and be =< 3 x ULN (must be within 7 days of MLA)
Alkaline phosphatase (ALP) =< 5.0 x ULN
Alkaline phosphatase (ALP) < 5 x upper limit of normal
Alkaline phosphatase (ALP) < 5 x normal
Alkaline phosphatase (ALP) levels > 2.5 × ULN.
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) and Alkaline Phosphatase (ALP) must be within the range allowing for eligibility: ALP normal AND AST or ALT =< 5 x ULN; ALP =< 3.5 x ULN AND AST or ALT =< 1.5 x ULN; OR ALP =< 5 x ULN AND ALT or AST =< ULN
Within 14 days prior to first dose of study drug treatment: Alkaline phosphatase (ALP) =< 3 x ULN with the following exceptions:\r\n* Patients with documented liver or bone metastases: ALP =< 5 x ULN
Alkaline phosphatase (ALP) < 3 x ULN
DOSE ESCALATION COHORT: Alkaline phosphatase (ALP) ? 2.5 X ULN
Alkaline phosphatase (ALP) > 250 U/L
AST(SGOT), ALT(SGPT), or alkaline phosphatase (ALP) ? 2.5 x ULN.
Alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ? 3 x ULN (? 5 x ULN if participant has liver metastases). If ALP is > 3 x ULN (in the absence of liver metastases) or > 5 x ULN (in the presence of liver metastases) AND participants are also known to have bone metastases, the liver-specific ALP must be separated from the total and used to assess the liver function instead of the total ALP.
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 × ULRR or alkaline phosphatase (ALP) > 2.5 x ULRR
Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) =< 2.5 x upper limit of normal (ULN), obtained within 14 days prior to initiation of study treatment, with the following exceptions: patients with documented liver metastases: AST and ALT =< 5 x ULN; patients with documented liver or bone metastases: alkaline phosphatase (ALP) =< 5 x ULN
Alkaline phosphatase (ALP) ? 3.0 × ULN (< 5 × ULN if isolated ALP increase, i.e., without ALT/AST or bilirubin increase).
Alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than or equal to 3 X ULN (less than or equal to 5 X ULN if participant has liver metastases). If ALP is greater than 3 X ULN (in the absence of liver metastases) or greater than 5 X ULN (in the presence of liver metastases) AND the participant also is known to have bone metastases, the liver-specific ALP must be separated from the total and used to assess the liver function instead of total ALP.
Alkaline phosphatase (ALP) >5 xULN
Alkaline phosphatase (ALP) =< 2.5 x ULN unless considered tumor-related
Alkaline phosphatase (ALP) =< 2.5 x ULN unless considered tumor related
Alkaline phosphatase (ALP) =< 2.5 x ULN unless considered tumor related
Alkaline phosphatase (ALP) =< 2.5 x ULN (within 7 days prior to registration)
Alkaline phosphatase (ALP) limit < 2.5 x ULN or =< 5.0 x ULN if liver metastases are present
Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ?2.5 × ULN. For subjects with bone metastases and/or suspected disease-related liver or biliary involvement, ALP must be ?5 × ULN.
If bone metastases are present and liver function is otherwise considered adequate by the Investigator then elevated alkaline phosphatase (ALP) will not exclude the patient.
Alkaline phosphatase (Alp) =< 2.5 x ULN
Alkaline phosphatase (ALP) =< 2.5 x ULN unless considered tumor related
Alkaline phosphatase (Alp) =< 2.5 x ULN
Alkaline phosphatase (ALP) ?5 × ULN (except for subjects with hepatomegaly and isozymes specific to liver, rather than bone)
Alkaline phosphatase (ALP) < 3 x UNL
Alkaline phosphatase (ALP) < 5 x upper limit of normal
Alkaline phosphatase (ALP) =< 2.5 x ULN, with the following exceptions: patients with documented liver or bone metastases: ALP =< 5 x ULN
Alkaline phosphatase (ALP) < 5 x ULN
ALP ? 3 x ULN or ? 5 x ULN if bone metastasis is present
Alkaline phosphatase =< 3 ULN; if total ALP is > 3 x ULN (in the absence of liver metastasis) or > 5 x ULN in subjects with liver metastasis AND the subject is known to have bone metastases, then liver ALP iso-enzyme should be used to assess liver function rather than total ALP
Alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than or equal to 3 times ULN. For total ALP greater than 3 times ULN, the ALP liver isoenzyme must be less than or equal to 3 times ULN.
Patients enrolled without hepatic dysfunction must have laboratory test results for total bilirubin of less than the ULN, alkaline phosphatase (ALP) <=1.5x the ULN, and AST and ALT of <=the ULN.
Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP): all three < 2.5 x ULRR, or < 5 x ULRR if judged by the investigator to be related to liver metastases
Bilirubin and Alkaline phosphatase (ALP) =< 2 x ULN
Alkaline phosphatase (ALP) =< 5.0 x ULN
Alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ?3 × ULN (?5 × ULN if participant has liver metastases). If ALP is >3 × ULN (in the absence of liver metastases) or >5 × ULN (in the presence of liver metastases) AND participants are also known to have bone metastases, the liver-specific ALP must be separated from the total and used to assess the liver function instead of the total ALP.
Alkaline phosphatase (ALP) > 2 x ULRR, or > 4 x ULRR if judged by the investigator to be related to liver metastases
Alkaline phosphatase (ALP) > 2.5 x ULRR
Individuals with alkaline phosphatase (ALP) > 2.5 x normal upper limit any time during the previous 2 months
Alkaline phosphate =< 3 x normal
Alkaline phosphatase within upper limits of institutional normal within 14 days prior to study entry
Alkaline phosphatase =< 2.5 x institutional upper limit of normal
Alkaline phosphatase < 2.5 x upper limit of normal if no documented liver disease or < 6 x upper limit of normal if documented liver or bone disease
Alkaline phosphatase =< 5 x upper limit of normal
Alkaline phosphatase =< 2.5 X institutional upper limit of normal, determined within 14 days of registration
Alkaline phosphatase =< 5 x upper limit normal (ULN)
PART I: Alkaline phosphatase (Alk PO4) =< 3 x the upper limits of normal (except for patients with documented metastatic disease to bone and/or liver)
Bilirubin <= 1.5 mg/dL; ALT, AST, and alkaline phosphatase <= 3.0x the upper limit of normal
Alkaline phosphatase =< 2 x upper limit of normal
Alkaline phosphatase =< 2.5 x upper limit of reference range (or =< 5 x upper limit of reference range if considered to be related to liver or bone metastases by the principal investigator [PI])
Alkaline phosphatase < 3 x institutional upper limit of normal (ULN)
Alkaline phosphatase >= 3 x institutional upper limit of normal (ULN)
Alkaline phosphatase =< 3 x upper limit of normal
Alkaline phosphatase =< 2.5 x institutional upper limit of normal
Alkaline phosphatase =< 3 X the upper limit of normal (ULN)
Alkaline phosphatase =< 3 x institutional upper limit of normal within 30 days of registration
Alkaline phosphatase < 5 x upper limit of normal
Bilirubin >2.0; alkaline phosphatase >5x upper limit of normal (ULN); ALT/AST >2x ULN.
Alkaline phosphatase =< 2.5 institutional upper limit of normal of =< 5 x ULN if liver metastases are present
Alkaline phosphatase =< 2.5 x normal prior to biopsy
Alkaline phosphatase > 5 X upper limits of normal (ULN)
Alkaline phosphatase levels =< 2.5 x upper limit of normal (ULN)
Alkaline phosphatase =< 2.5 x upper limit (UL)
Alkaline phosphatase < 5 x upper limit of normal (ULN)
Alkaline phosphatase =< 2 x upper limit of normal, unless proven to be due to disease involvement
ADDITIONAL CRITERIA FOR STUDY CONTINUATION: Alkaline phosphatase (alk phos) =< 5 X upper level of normal
Alkaline phosphatase < 2.5 x upper limit of normal
Alkaline phosphatase < 3 x upper limit of normal (ULN)
Alkaline phosphatase < 2 x upper limit of normal
Alkaline phosphatase < 2 upper limit of normal (ULN)
Alkaline phosphatase less than 1.5 x upper limit of normal
Alkaline (Alk) phosphatase (Phos) =< 5 x upper limit of normal
Alkaline phosphatase must be =< 4 x the institutional upper limit of normal (ULN)
Alkaline phosphatase =< 5 x the upper limit of normal; serum bilirubin > 2.0 is acceptable in the setting of known Gilbert’s syndrome
Bilirubin, aspartate aminotransferase (AST), alkaline phosphatase (ALK) =< 2 x normal
Aspartate aminotransferase (AST) and alkaline phosphatase < 5 x upper limit of normal
AST and alkaline phosphatase < 5 x upper limit of normal
Alkaline phosphatase level =< upper limit of normal (ULN)
Alkaline phosphatase (ALK Phos) =< 2.5 X institutional upper limit of normal
Alkaline phosphatase =< 4 x institutional upper limit of normal (IULN)
Alkaline (Alk) phosphatase =< 5 x upper limit of normal
Alkaline phosphatase > 3 x normal
Within 14 days of registration: Alkaline phosphatase =< 5 x upper limit of normal
Alkaline phosphatase =< 2.5 x institutional upper limit of normal
Alkaline phosphatase =< 3 X institutional upper limit of normal
Alkaline phosphatase =< 3 X institutional upper limit of normal
No history of severe prior or ongoing chronic liver disease; alkaline phosphatase < 5 x upper limit of normal
Alkaline phosphatase =< 2.5 x upper limit of normal
Alkaline phosphatase =< 3 x institutional normal
Alkaline phosphatase =< 5 X upper limit of normal (ULN)
Alkaline phosphatase < 2 x upper limit of normal, or considered not clinically significant by the study doctor or designee
Alkaline phosphatase < 5 x upper limit normal (ULN)
Within 14 days of registration: Alkaline phosphatase =< 2.5 × institutional upper limit of normal
Alkaline phosphatase =< 3 X the upper limit of normal (ULN)
Alkaline phosphates must be =< 2.5 X the upper limit of normal
Alkaline phosphatase (AP) =< 3 x institutional upper limit of normal
Alkaline phosphatase =< 2.5 x upper limit of normal (ULN)
Alkaline phosphatase =< 2.5 x institutional upper limit normal
Alkaline phosphatase =< 2.5 x normal prior to biopsy
Alkaline phosphatase ? 2.5 x upper limit of normal (ULN)
Alkaline phosphatase =< 2.5 x normal limits
Alkaline phosphatase =< upper limit of normal (ULN) and AST or ALT =< ULN eligible
Alkaline phosphatase less than or equal to 2.5 x upper limit of normal, CTCAE v 4.0 grade 1
Alkaline phosphatase =< 2.5 x upper limit of normal (ULN)
Alkaline phosphatase =< 2.5 X upper limit of normal
Alkaline phosphatase =< 1.5 x upper limit of normal
Alkaline phosphatase =< 2.5 x upper limit of normal (ULN)
Alkaline phosphatase =< 2 x upper limit of normal
Alkaline phosphatase > 2 x upper limits of normal (ULN)
Alkaline phosphatase =< 2.5 X upper limit of normal
Alkaline phosphatase < 2 X upper limit of normal
Alkaline phosphatase =< 2.5 x upper limit of normal (ULN)
Alkaline phosphatase < 3 x upper limit of normal
Alkaline phosphatase < 2.5 X institutional upper limit of normal
Alkaline phosphatase =< 5x upper limit of normal
Alkaline phosphatase =< 1.5 x upper limit of normal (ULN).
Obtained =< 30 days prior to registration: Alkaline phosphatase =< 3 x the institutional upper limit of normal
Alkaline phosphatase =< 2.5 x the upper normal limit
Alkaline phosphatase =< 2.5 X upper limit of normal; in patients with bone metastasis and no evidence of liver metastasis and bilirubin =< upper limit of normal an alkaline phosphatase =< 5 ULN will be allowed
Alkaline phosphatase =< 2.5 x upper limit of normal
Alkaline phosphatase < 5 x upper limit of normal
Alkaline phosphatase =< 1.5 x institutional upper limit of normal (ULN)
Alkaline phosphatase (ALK) =< 1.5 x upper limit of normal (ULN)
Liver alkaline phosphatase =< 3 x upper limit of normal
Alkaline phosphatase < 2.5 x the upper limit of normal
Alkaline phosphatase =< 1.5 x upper limit of institutional normal
Alkaline phosphatase =< 1.5 x institutional upper limit of normal
Alkaline phosphatase must be less than 4 x upper limit of normal
Alkaline phosphatase =< 2.5 x upper limits of normal if no liver metastases present; alkaline phosphatase =< 5 x upper limits of normal if liver metastases present
Alkaline phosphatase within normal limits
Alkaline phosphatase (Alk phos) =< 2.5 X institutional upper limit of normal
Alkaline phosphatase =< 2.5 x ULN (=< 5 x ULN for patients with documented liver involvement or bone metastases)
Obtained within 28 days prior randomization: alkaline phosphatase must be =< 2.5 x ULN for the lab with the following exception: patients with documented liver metastases or bone involvement - alkaline phosphatase must be =< 5 x ULN; and
Alkaline phosphatase =< 2.5 x ULN (=< 5 x ULN for patients with documented liver involvement or bone metastases)
Serum alkaline phosphatase =< 3 x upper limit of normal (ULN) in absence of liver or bone metastases and =< 5 x ULN in patients with documented bone or liver metastases
Alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than or equal to 3 X ULN (less than or equal to 5 X ULN if participant has liver metastases). If alkaline phosphatase is greater than 3 X ULN (in absence of liver metastases) or greater than 5 X ULN (in presence of liver metastases) AND the participant also is known to have bone metastases, the liver-specific alkaline phosphatase must be separated from the total and used to assess the liver function instead of total alkaline phosphatase
Alkaline phosphatase =< 2.5 x ULN (=< 5 x ULN for patients with documented liver involvement or bone metastases)
Alkaline phosphatase =< 2.5 x upper limit of normal (ULN) or =< 5 X ULN if bone metastases (mets) are present
Alkaline phosphatase ? 3 x ULN or ? 5 x ULN if bone metastasis is present
Alkaline phosphatase =< 2.5 x ULN or =< 5 x ULN if judged by the investigator to be related to liver metastases
Alkaline phosphatase =< 2.5 x ULN with the following exception: patients with documented liver involvement or bone metastases: alkaline phosphatase =< 5 x ULN.
STUDY TREATMENT: Alkaline phosphatase =< 2.5 × ULN within 14 days prior to the first study treatment with the following exception:\r\n* Patients with documented liver involvement or bone metastases: alkaline phosphatase =< 5 ×ULN.
Alkaline phosphatase =< 2.5 x ULN; =< 5 x ULN for patients with documented liver involvement or bone metastases.
Alkaline phosphatase, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?3 × ULN (in the case of liver metastases ?5 × ULN), unless there are bone metastases, in which case liver-specific alkaline phosphatase must be separated from the total and used to assess the liver function instead of the total alkaline phosphatase.
Alkaline phosphatase =< 2.5 x ULN with the exception that patients with documented liver involvement or bone metastases: alkaline phosphatase =< 5 x ULN
Obtained within 14 days prior to the first study treatment (cycle 1, day 1): alkaline phosphatase =< 2.5 x ULN with the following exception: 1) =< 5 x ULN in patients with documented liver metastases =< 7 x ULN in patients with documented bone metastases
Alkaline phosphatase must be =< 2.5 x ULN (unless elevated alkaline phosphatase clearly due to skeletal—rather than hepatic—process; eg, normal gamma-glutamyltransferase (GGT), presence of multiple bone metastases, absence of bulky and/or central liver metastases). Patients with Gilbert’s syndrome are allowed if total bilirubin =< 2 x ULN and direct bilirubin is =< ULN
Alkaline phosphatase =< 2.5 x ULN with the following exception:\r\n* Patients with documented liver involvement or bone metastases: alkaline phosphatase =< 5 x ULN
Alkaline phosphatase =< 2.5 x ULN (obtained within 28 days prior to first study treatment)\r\n* Subjects with documented liver or bone metastases should have alkaline phosphatase =< 5 x ULN
Alkaline phosphatase ? 2.5 x ULN within 14 days prior to the first study treatment (cycle 1, day 1) with the following exception:\r\n? Patients with documented liver involvement or bone metastases: alkaline phosphatase ? 5 x ULN
Alkaline phosphatase =< 2.5 x ULN unless bone metastases present
Alkaline phosphatase =< 2.5 x ULN (=< 5 x ULN if bone or liver metastases present)
Alkaline phosphatase ? 2.5 x ULN (? 5.0 x ULN if bone or liver metastases present)
For subjects without extensive bone metastases: alkaline phosphatase levels < 2.5 x ULN
REGORAFENIB INCLUSION CRITERIA: Alkaline phosphatase (ALP) =< 2.5 x ULN if no liver metastases are present; =< 5 x ULN if bone or liver metastases are present
Alkaline phosphatase < 2.5 upper limit of normal (ULN) (< 10 x ULN in presence of bone metastases) within 14 days of study entry
Alkaline phosphatase =< 2.5 x ULN for the laboratory (=< 5 x ULN for patients with cancer involving the liver and/or bone)
Alkaline phosphatase =< 3 x ULN (in the case of liver metastases, =< 5 x ULN)
Alkaline phosphatase ? 2.5 × ULN (? 5 ± ULN for patients with documented liver involvement or bone metastases)
Within 14 days prior to the first study treatment (cycle 1, day 1): Alkaline phosphatase =< 2.5 x ULN with the following exception: Patients with documented bone metastases: alkaline phosphatase =< 5 x ULN.
Alkaline phosphatase =< 2.5 x ULN, obtained within 14 days prior to the first study treatment (cycle 1, day 1) with the following exception:\r\n* Patients with documented liver or bone metastases may enroll with alkaline phosphatase =< 5 x ULN
Alkaline phosphatase < 2.0 x ULN (if liver or bone disease are present, < 3.0 x ULN)
Alkaline phosphatase =< 2 x ULN (=< 5 x ULN for patients with documented liver involvement or bone metastases)
Alkaline phosphatase (ALP) =< 1.5 x ULN but =< 2.5 x ULN in case of liver metastases or =< 5 x ULN in the case of bone metastasis; in the presence of liver metastases the liver isoenzyme fraction must be measured and liver\r\nisoenzyme fraction (absolute value) must be =< 2 x UNL
Alkaline phosphatase =< 2.5 x ULN with the following exception: \r\n* Patients with documented liver involvement or bone metastases: \r\n** Alkaline phosphatase =< 5 x ULN
Alkaline phosphatase =< 3.0 x ULN; up to 5 x ULN is acceptable if due to bone metastases in the absence of liver metastases
Alkaline phosphatase <3.0 x ULN or ?5.0 x ULN if liver or bone metastases present
Alkaline phosphatase <3.0 x ULN or ?5.0 x ULN if liver or bone metastases present
Alkaline phosphatase < 2.0 x ULN (if liver or bone metastases are present, < 3.0 x ULN)
Within 14 days of enrollment: Alkaline phosphatase =< 2.5 x ULN for the institution\r\n* For patients in the metastatic cohort with documented liver or bone metastases cohort with documented liver or bone metastases: alkaline phosphatase =< 5 x ULN
Alkaline phosphatase < 2 x ULN (if known liver or bone disease)
Obtained within 14 days prior to the first study treatment (cycle 1, day 1); alkaline phosphatase ? 2.5 x ULN with the following exception:\r\n* Patients with documented liver involvement or bone metastases: alkaline phosphatase ? 5 x ULN
Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) less than or equal 3 x ULN (less than or equal 5 x ULN if subject has liver metastases). If alkaline phosphatase is greater than 3 x ULN (in absence of liver metastases) or greater than 5 x ULN (in presence of liver metastases) AND the subject also is known to have bone metastases, the liver-specific alkaline phosphatase must be separated from the total and used to assess the liver function instead of total alkaline phosphatase.
Alkaline phosphatase (AP) =< 3 x the ULN or =< 5 × the ULN in the presence of known liver metastases
For subjects without extensive bone metastases: alkaline phosphatase levels =< 2.5 x ULN
For subjects with extensive bone metastases: alkaline phosphatase levels =< 5 x ULN
Alkaline phosphatase =< 2.5 x ULN (=< 5 x ULN for patients with documented liver involvement or bone metastases)
Alkaline phosphatase =< 2.5 x ULN (obtained within 14 days prior to the first study treatment [course 1, day 1]) with the following exception:\r\n* Patients with documented liver involvement or bone metastases: alkaline phosphatase =< 5 x ULN
Serum alkaline phosphatase ? 3x ULN (upper limit of normal)in the absence of liver or bone metastases or ?5 ULN(in patients with documented bone or liver metastases)
Alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) <=3*ULN unless there are bone metastases, in which case liver specific alkaline phosphatase must be separated from the total and used to assess the liver function instead of the total alkaline phosphatase. ALT and AST <= 5*ULN if participant has liver metastases.
Alkaline phosphatase =< 2.0 x ULN; if bone or liver metastases are present, =< 5 x ULN
For patients with known bone metastases, alkaline phosphatase < 5 x ULN is acceptable
Obtained within 28 days prior to registration: Alkaline phosphatase =< 2.5 x ULN (subjects with documented liver or bone metastases should have alkaline phosphatase =< 5 x ULN)
Alkaline phosphatase < 2.5 × ULN unless hepatic metastases are present, then < 5 × ULN
Alkaline phosphatase =< 2.5 x ULN in the absence of known bone metastases or =< 5.0 x ULN in the case of bone metastases
Alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ?3 × ULN (?5 × ULN if participant has liver metastases). If alkaline phosphatase is >3 × ULN (in absence of liver metastases) or >5 × ULN (in presence of liver metastases) AND the participant also is known to have bone metastases, the liver-specific alkaline phosphatase must be separated from the total and used to assess the liver function instead of total alkaline phosphatase.
Alkaline phosphatase =< 2.5 x IULN, unless bone metastasis is present in the absence of liver metastasis
Aspartate transaminase (AST) and alanine transaminase (ALT) ?2.5 x ULN for the institution, alkaline phosphatase ? 2.5 x ULN for the institution, unless bone metastasis is present in the absence of liver metastasis
Patients with any elevated alkaline phosphatase due to bone metastasis can be enrolled
Adequate liver function as demonstrated by: Total bilirubin of ?1.5 mg/dL or ?2.0 mg/dL for subjects with liver metastasis, Alanine aminotransferase (ALT) ?3 x upper limit of normal (ULN) or ?5 x ULN if liver metastasis is present, Alkaline phosphatase ?3 x ULN or ?5 x ULN if bone or liver metastasis is present, Gamma-glutamyl transferase (GGT) <10 x ULN
Alkaline phosphatase < 2.5 x upper limit of normal, unless bone metastasis is present (< 5 x upper limit of normal) in the absence of liver metastasis
Alkaline phosphatase =< 2.5 X ULN, unless bone metastasis is present (< 5 X ULN) in the absence of liver metastasis
Alkaline phosphatase > 2.5 x the ULN, there is no upper limit if bone metastasis is present in the absence of liver metastasis
Alkaline phosphatase =< 2.5 x ULN, unless bone metastasis is present in the absence of liver metastasis
Alkaline phosphatase =< 2.5 X upper limit of normal, unless bone metastasis is present in the absence of liver metastasis
Obtained within 28 days prior to registration: Alkaline phosphatase =< 2.5 x upper limit of normal, unless bone or liver metastasis is present (=< 5 x upper limit of normal)
Alkaline phosphatase =< 2.5 x upper limit of normal unless bone metastasis are present in the absence of liver metastases
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 X upper limit of normal, unless bone metastasis is present in the absence of liver metastasis
Alkaline phosphatase =< 2.5 X upper limit of normal, unless bone metastasis is present in the absence of liver metastasis
Alkaline phosphatase =< 2.5 times the upper limit of normal in the absence of liver metastasis; alkaline phosphatase < 5.0 times ULN in the presence of liver metastasis
Alkaline phosphatase =< 2.5 times upper limit of normal, unless bone metastasis is present in the absence of liver metastasis
Alkaline phosphatase ?2.0 x ULN or ?5 x ULN in case of bone metastasis and/or hepatic metastasis
Alkaline phosphatase =< 2.5 times the upper limit of normal, unless bone metastasis is present in the absence of liver metastasis
Alkaline phosphatase =< 2.5 x ULN; if bone metastasis is present in the absence of liver metastasis then =< 5 x ULN
Alkaline phosphatase < 2.5 x institutional upper limit of normal (in subjects with no liver metastasis and < 5.0 upper limit of normal [ULN] in subjects with liver metastasis)
Alkaline phosphatase =< 2.5 X upper limit of normal, unless bone metastasis in present in the absence of liver metastasis
Alkaline phosphatase =< 2.5 X upper limit of normal in the absence of liver or bone metastasis, or =< 5.0 x upper limit of normal range if bone or liver metastases
Alkaline phosphatase =< 2.5 X institutional upper limit of normal, unless bone metastasis is present in the absence of liver metastasis
Alkaline phosphatase =< 2.5 x ULN (unless bone metastasis is present in the absence of liver metastasis, in which case 3.0 x ULN would be acceptable)
Alkaline phosphatase =< 2.5 x upper limit of normal (< 5 X ULN for subjects with bone or liver metastasis)
Alkaline phosphatase < 2.5 times the upper limit of normal, unless bone metastasis is present in the absence of liver metastasis
Adequate liver function as demonstrated by:Total bilirubin of ?1.5 mg/dL or ?2.0 mg/dL for subjects with liver metastasis, Alanine aminotransferase ?3 x upper limit of normal (ULN) or ?5 x ULN if liver metastasis is present, Alkaline phosphatase ?3 x ULN or ?5 x ULN if bone or liver metastasis is present